May 24 2022 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter December 15 2021 GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster December 13 2021 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
May 04 2022 GeoVax Announces Upcoming Presentations at Scientific Conferences April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter December 15 2021 GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster December 13 2021 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
April 27 2022 GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter December 15 2021 GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster December 13 2021 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
April 26 2022 GeoVax Announces Issuance of Malaria Vaccine Patent April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter December 15 2021 GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster December 13 2021 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
April 19 2022 GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter December 15 2021 GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster December 13 2021 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
April 12 2022 GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter December 15 2021 GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster December 13 2021 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
March 22 2022 GeoVax Announces Issuance of Cancer Vaccine Patent March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter December 15 2021 GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster December 13 2021 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
March 21 2022 GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022 March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter December 15 2021 GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster December 13 2021 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
March 16 2022 GeoVax to Participate in Maxim Group’s 2022 Virtual Growth Conference March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter December 15 2021 GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster December 13 2021 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
March 14 2022 GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter December 15 2021 GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster December 13 2021 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
March 10 2022 Data published in a Lancet journal on COH04S1, a City of Hope-developed COVID-19 vaccine, shows it produced robust antibodies and T cells against SARS-CoV-2 March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter December 15 2021 GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster December 13 2021 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
March 09 2022 GeoVax Reports 2021 Year-End Financial Results And Provides Corporate Update March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter December 15 2021 GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster December 13 2021 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
March 07 2022 GeoVax Announces Key Staff Appointments February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter December 15 2021 GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster December 13 2021 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
February 23 2022 GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter December 15 2021 GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster December 13 2021 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
February 22 2022 GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100 February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter December 15 2021 GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster December 13 2021 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
February 08 2022 GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter December 15 2021 GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster December 13 2021 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
January 20 2022 GeoVax Announces Closing of $10 Million Private Placement January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter December 15 2021 GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster December 13 2021 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
January 14 2022 GeoVax Announces $10 Million Private Placement January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter December 15 2021 GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster December 13 2021 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
January 13 2022 GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter December 15 2021 GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster December 13 2021 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
January 11 2022 GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter December 15 2021 GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster December 13 2021 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
January 05 2022 GeoVax to Participate in Upcoming Life Sciences Investor Conferences January 04 2022 GeoVax Issues Shareholder Update Letter December 15 2021 GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster December 13 2021 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
January 04 2022 GeoVax Issues Shareholder Update Letter December 15 2021 GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster December 13 2021 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
December 15 2021 GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster December 13 2021 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
December 13 2021 GeoVax Receives Notice of Allowance for Malaria Vaccine Patent December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
December 03 2021 GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
December 01 2021 GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
November 16 2021 GeoVax Presents COVID-19 Vaccine Data at the Vaccine World Asia Congress November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
November 16 2021 GeoVax Receives Notice of Allowance for Cancer Vaccine Patent November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
November 15 2021 GeoVax Announces Upcoming Presentations at Scientific Conferences November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
November 11 2021 GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
November 09 2021 GeoVax and City of Hope Announce Agreement to Accelerate Development and Commercialization for City of Hope’s COVID-19 Vaccine November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
November 04 2021 GeoVax to Report Third Quarter 2021 Financial Results on Thursday, November 11, 2021 and Provide Corporate Update October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
October 18 2021 GeoVax Chief Scientific Officer to Participate in World Vaccine Congress Europe October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
October 14 2021 GeoVax Receives Notice of Allowance for Ebola Vaccine Patent September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
September 28 2021 GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
September 07 2021 GeoVax to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
August 19 2021 GeoVax Presents COVID-19 Vaccine Data at the European Society of Medicine (ESMED) General Assembly August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
August 12 2021 GeoVax to Present at the SNN Network Summer Virtual Event on Wednesday, August 18, 2021 August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
August 11 2021 GeoVax Reports 2021 Second Quarter Financial Results and Provides Corporate Update August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
August 04 2021 GeoVax to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021 and Provide Corporate Update July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
July 22 2021 GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at the American Society for Virology Annual Meeting July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
July 02 2021 GeoVax Announces Issuance of Hepatitis B Vaccine Patent June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
June 10 2021 GeoVax to Participate in the Alliance Global Partners’ Virtual Healthcare Symposium June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
June 07 2021 GeoVax to Present at 2021 BIO Digital May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
May 11 2021 GeoVax Labs, Inc. Invites You to Join Us at the Q2 Virtual Investor Summit May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
May 06 2021 GeoVax Reports 2021 First Quarter Financial Results and Provides Corporate Update May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
May 06 2021 GeoVax to Present to Investors at the Benzinga Global Small Cap Conference on May 13, 2021 April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
April 26 2021 GeoVax to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021 and Provide Corporate Update April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
April 01 2021 GeoVax Receives Notice of Allowance for Hepatitis B Vaccine Patent March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
March 23 2021 GeoVax Reports 2020 Year-End Financial Results And Provides Corporate Update March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
March 17 2021 GeoVax to Participate in Benzinga Biotech Small Cap Conference March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
March 15 2021 GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
March 10 2021 GeoVax to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
March 04 2021 GeoVax Expands and Strengthens Intellectual Property Portfolio March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
March 03 2021 GeoVax to Present at the H.C. Wainwright Global Life Sciences Conference March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
March 01 2021 Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond” Featuring GeoVax’s CEO & CFO On March 3, 2021 February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
February 11 2021 GeoVax Announces Closing of $10.3 Million Bought Deal Offering February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
February 09 2021 GeoVax Announces Pricing of $9.0 Million Bought Deal Offering January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
January 11 2021 GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
January 05 2021 GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
November 30 2020 GeoVax Announces License Agreement with NIH to Support Continued Advancements in Vaccine Development November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
November 05 2020 GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
October 30 2020 GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
October 28 2020 GeoVax CEO David Dodd to Participate in Virtual Webinar hosted by Outsourced Pharma October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
October 26 2020 GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
September 29 2020 GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
September 25 2020 GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
September 15 2020 GeoVax to Participate in World Vaccine Congress Session Addressing the Global Need for an HIV Vaccine September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
September 03 2020 GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate against Marburg Virus Showing 100% Protection August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
August 26 2020 GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
August 24 2020 GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
August 13 2020 GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
August 10 2020 GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
June 29 2020 GeoVax Announces Closing of $1 Million Private Placement June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
June 29 2020 GeoVax to Participate in International Webinar Focused on the State of COVID-19 Vaccines June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
June 10 2020 GeoVax to Present COVID-19 Vaccine Program at National Foundation for Infectious Diseases Annual Conference on Vaccinology Research June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
June 04 2020 GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
May 06 2020 GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
April 30 2020 GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
March 30 2020 GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
March 25 2020 GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
March 18 2020 GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
March 04 2020 GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
February 27 2020 GeoVax to Present at World Immunotherapy Congress 2020 February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
February 06 2020 GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
January 27 2020 GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
January 23 2020 GeoVax Announces Reverse Stock Split December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
December 03 2019 GeoVax to Present at World Vaccine & Immunotherapy Conference December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
December 02 2019 GeoVax Observes 2019 World AIDS Day November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
November 14 2019 GeoVax to Present at Vaccines R&D Conference November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
November 13 2019 GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
November 11 2019 GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
October 24 2019 GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
October 15 2019 GeoVax Presenting at Upcoming October European Scientific Conferences October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
October 03 2019 GeoVax CEO Q&A: Answering Shareholder's Questions October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
October 01 2019 GeoVax CEO Comments on Recent Changes in Capital Structure September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
September 09 2019 Leveraging GeoVax's Vaccine Expertise To Take On Cancer September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
September 04 2019 GeoVax Announces Publication of Lassa Fever Vaccine Study Results August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
August 14 2019 GeoVax Reports 2019 Second Quarter Financial Results and Highlights Corporate Development Progress May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
May 22 2019 GeoVax to Conduct Partnering Meetings During BIO International Convention June 3-6, 2019 May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
May 16 2019 GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
May 15 2019 GeoVax to Present Unique Technology at New York Academy of Sciences Vaccine Conference May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
May 14 2019 GeoVax Reports 2019 First Quarter Financial Results and Highlights Corporate Development Progress May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
May 03 2019 GeoVax Announces Reverse Stock Split April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
April 24 2019 GeoVax Recognizes World Malaria Day 2019 March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
March 27 2019 GeoVax Reports 2018 Year-End Financial Results March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
March 19 2019 GeoVax Ebola Vaccine Study Published in the Atlas of Science March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
March 12 2019 GeoVax Selected as Finalist for Vaccine Industry Excellence Awards March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
March 11 2019 GeoVax Provides Product Development and Corporate Update March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
March 04 2019 GeoVax and Leidos Expand Collaboration to Malaria Vaccines February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
February 14 2019 GeoVax Issues Open Letter to HHS Secretary Alex Azar February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
February 07 2019 GeoVax Recognizes National Black HIV/AIDS Awareness Day February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
February 06 2019 GeoVax CEO David Dodd Responds to President Trump’s State of the Union Message January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
January 24 2019 GeoVax Zika Vaccine Study Published in the Atlas of Science January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
January 22 2019 GeoVax to Present at the 2019 ASM Biothreats Conference January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
January 02 2019 GeoVax and Enesi Pharma to Collaborate On Development of Multiple Vaccines Administered by ImplaVax® a Novel Needle-Free Vaccine Delivery Platform December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
December 12 2018 GeoVax Comments on 2018 Ebola Outbreak December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
December 03 2018 GeoVax Observes 2018 World AIDS Day November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
November 28 2018 GeoVax Provides Update on HIV Clinical Trials Program November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
November 19 2018 GeoVax and Leidos Enter into a Collaboration Agreement on Immunotherapy Research Program
